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Question under study: Pulmonary function test-
ing (PFT) in longitudinal studies involves the re-
peated use of spirometers over long time periods.
We assess the comparability of PFT results taken
under biologic field conditions using thirteen cer-
tified devices of various technology and age. Com-
parability of measurements across devices and over
time is relevant both in clinical and epidemiologi-
cal research.
Methods: Forced Vital Capacity (FVC), Forced
Expiratory Volume in the first second (FEV1) and
Forced Expiratory Flow 50% (FEF50) were com-
pared before and after the data collection of the
Swiss Study on Air Pollution and Lung Diseases in
Adults (SAPALDIA) and the European Commu-
nity Respiratory Health Survey (ECRHS) cohort
studies. Three test series were conducted with 46,
50 and 56 volunteers using various combinations
of spirometers to compare the eight flow-sensing
spirometers (Sensormedics 2200) used in the
SAPALDIA cross-sectional and follow-up, two
new flow-sensing instruments (Sensormedics Vmax)
and three volume displacement spirometers (two
Biomedin/Baires and one Sensormedics 2400). 
Results: The initial comparison (1999/2000) of
eight Sensormedics 2200 and the follow-up com-
parison (2003) of the same devices revealed a max-
imal variation of up to 2.6% for FVC, 2.4% for
FEV1 and 2.8% for FEF50 across devices with no
indication of systematic differences between
spirometers. Results were also reproducible be-
tween Biomedin, Sensormedics 2200 and 2400.
The new generation of Sensormedics (Vmax) gave
systematically lower results. 
Conclusions: The study demonstrates the need
to conduct spirometer comparison tests with hu-
mans. For follow-up studies we strongly recom-
mend the use of the same spirometers.
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cohort studies; lung function measurements
Forced expiratory lung function measure-
ments are an objective indicator of cardio-respira-
tory health, being related to both acute and long-
term morbidity and mortality [1–4] To investigate
environmental determinants of lung function
growth in children [5] and decline among adults
such as in the Swiss Study on Air Pollution and
Lung Diseases (SAPALDIA) [6] and the European
Community Respiratory Health Survey (ECRHS)
[7], repeated measurements of lung function are
required across longer time periods [8, 9]. In the
first quality control studies we assessed the com-
parability of different devices, teams and field-
workers during the cross-sectional SAPALDIA
study to ensure unbiased comparisons across com-
munities and sufficient precision to detect small
differences [10, 11]. To investigate determinants of
lung function change over time, measurement
quality and standard procedures need to remain
constant not only across fieldworkers, teams, and
centres [11] but also over time. We now address
key challenges faced by multi-centre follow-up
studies that repeat spirometries after several years.
Similar to clinical settings, follow-up studies have
to consider revisions or replacement of equipment
and/or updates of software. Systematic differences
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of a few percent between devices may not influence
clinical decisions but could have devastating effects
in research. Therefore, we conducted a total of
three comparison tests. The goals of the first two
test series were to compare the performance of the
eight formerly used SAPALDIA spirometers (Sen-
sormedics, Yorba Linda, USA) with each other,
with the same reference instrument used in the
1992 comparison test [11], with a new generation
of Sensormedics devices (Vmax 22), and with the
spirometers used in most of the ECRHS centres
(Biomedin Baires, Padova, Italy) since a subgroup
of SAPALDIA belongs to ECRHS. The results of
these tests led to the conclusion to again use the
instruments from SAPALDIA 1 in SAPALDIA 2
[8]. The goal of the third test series was a compar-
ison across the eight spirometers used in SAPAL-
DIA 2 to assess device comparability at completion
of the follow-up. We will discuss the implications
of these comparison tests on long-term research
projects.
Methods
Subjects and sessions
Subjects in all tests were healthy non-smoking male
and female volunteers recruited for each test series sepa-
rately from the student body of the University of Basel.
We chose the sample sizes of the different comparison
tests in such a way as to guarantee that a true 3%-range in
the average volume measurements of the spirometers
under comparison would be detected at the 5%-signi-
ficance level with a probability of 80%. Power was esti-
mated using the SAS-Macro fpower from M. Friendly
(http://www.math.yorku.ca/SCS/sasmac/fpower.html).
Volunteers performed forced expiratory pulmonary
function testing (PFT) using each spirometer in the test
series. A Latin square design was used to determine the
order of devices. These sessions consisted of at least three
and up to eight manoeuvres at each spirometer (seated po-
sition) until ATS acceptability and repeatability criteria
were fulfilled. Quality control, acceptability and repeata-
bility criteria, and manoeuvre selection procedures were
identical to those employed in SAPALDIA 1 and ECRHS,
and met the American Thoracic Society (ATS) standards
[6, 9, 12]. The session at the first spirometer was consid-
ered a practice session, thus, the data were barred from the
analysis and students had to perform again at this instru-
ment later on in their circuit. 
Spirometers
The spirometers used were Sensormedics 2200, 
Sensormedics 2400, Sensormedics Vmax 22 (all from 
Yorba Linda, USA, distributor Gambro AG/Pilger-AG,
Switzerland) and Biomedin Baires (Biomedin, Padova,
Italy). Sensormedics 2200 and Sensormedics Vmax are
flow-sensing spirometers (heated wire), whereas Sen-
sormedics 2400 (dry rolling seal) and Biomedin Baires
(water seal) are volume-displacement spirometers. In our
first device comparison [11] we compared the flow sens-
ing devices with the traditional dry rolling seal instru-
ments (Sensormedics 2400); thus, we considered the lat-
ter as our “reference device”.
All instruments measured with conventional body
temperature, pressure and saturation (BTPS) corrections.
Calibration of spirometers
Devices were calibrated with 3-litre syringes at least
twice a day and when instruments were switched on. Since
the Biomedin syringe tube did not fit on Sensormedics
spirometers we had to use two syringes. Digital measure-
ments of room temperature and air pressure were entered
into the spirometer software before calibration was per-
formed. The calibration was conducted at varying speeds
and considered successful when the inspired and expired
manoeuvres measured between 99% and 101% of the
volume. All calibrations performed during all test series
met these requirements prior to starting the tests.
Three test series
Table 1 presents the time period, sample size and de-
vices relevant to each test series. All series were conducted
in the same two adjacent rooms with stable room temper-
ature. Test series 1 included the eight SAPALDIA instru-
ments used in SAPALDIA 1 (Sensormedics 2200; Yorba
Linda, USA) and one device (Vmax #1) of the new genera-
tion of mass flow meter (Sensormedics, Vmax 22 Yorba
Linda, USA). Test series 2 compared two new Bio-
medin/Baires instruments (Biomedin; Padova, Italy), two
Factor test series 1 test series 2 test series 3
Test dates (each series took 3 days) Nov. 1999 Jan. 2000 June 2003
Subjects (N) 46 50 56
Females (in %) 49.3 52.3 51.7
Mean (SD) age (years) 24.1 (6.5) 24.3 (5.2) 25.4 (5.6)
Mean (SD) height (cm) 173.4 (9.3) 172.8 (8.6) 173.2 (8.3)
Number of devices (Number of tests)a 9 (414) 6 (300) 8 (448)
Devices tested
Sensormedics (Yorba Linda, CA, USA)
– 2200 hot wire flow meterb device S1 to S8 S2 , S3 device S1 to S8
– 2400 dry seal spirometer – S-ref –
– Vmax hot wire flow sensor Vmax #1 Vmax #2 –
Biomedin Baires (Padova, Italy)
– Biomedin water seal spirometer – B1, B2 –
a Number of tests = number of subjects  number of devices included in the test series
b These eight devices have been used in SAPALDIA 1 and SAPALDIA 2
Table 1
Description of three
spirometer compari-
son test series.
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Characteristics for all test series are shown in
table 1. 
Test series 1
Figure 1 displays the mean (and 95% confi-
dence interval) of the percent deviation from the
personal mean FVC across all instruments for each
device of test series 1. Results for FEV1 and FEF50
are not shown, as these are practically identical.
The average deviations from the personal means
observed for Vmax #1 were all statistically signifi-
cant and reached –4.5%, –4.5%, and –7.6% for
FVC, FEV1 and FEF50 respectively. Comparison
of results after exclusion of the Vmax spirometer
resulted in mean deviations within ±1.1%, ±1.7%,
and ±2.1%, respectively. The difference between
the devices with the smallest and largest mean was
statistically significant only in the case of FEV1
(deviation from mean –1.2% versus +1.7%).
Test series 2
Figure 2 presents the device specific deviations
from the personal mean FVC. Values from Vmax #2
spirometer were significantly lower than those on
any other device with deviations of –7.5% for
FVC, –8.4% for FEV1 and –11.3% for FEF50. Ex-
clusion of this device revealed similar deviations 
as in test series 1 after exclusion of the Vmax #1
spirometer. The deviations were within ±2.3%,
±1.9, and ±2.2%, respectively. The differences
between the lowest and highest deviation were
statistically significant in all three parameters.
Test series 3
Figure 3 presents the mean percent deviation
of FVC for all eight SAPALDIA devices as ob-
served at the completion of SAPALDIA 2. Devia-
tions were within ±2.6%, ±2.4%, and ±2.8% for
FVC, FEV, and FEF50, respectively and reached
statistical significance between the extremes.
of the above mentioned eight SAPALDIA 1 devices (Sen-
sormedics 2200), one Sensormedics 2400 (Yorba Linda,
USA), already used as a “reference” in the 1992 compari-
son [11] and a second new Sensormedics (Vmax #2). Test
series 3 compared the eight SAPALDIA 1 instruments
(Sensormedics 2200) at completion of SAPALDIA 2.
Technicians
All measurements in test series 1 and 2 were coached
by the same technician. A second fieldworker conducted
test series 3. Both technicians had worked for SAPALDIA
and in lung function laboratories for at least one year doing
daily routine measurements.
Analysis of spirometric data
We present results for forced vital capacity (FVC),
forced expiratory volume in one second (FEV1) and the
mid-expiratory flow, FEF50, taken from the best manoeu-
vre. The personal means across all devices in the test 
series were calculated for each parameter. The deviation
from this personal mean was derived for each person and
spirometer. We compare the device-specific means of
these deviations. 
We used three-way-ANOVA to detect differences
due to spirometers, subjects and order of testing, since
each subject was tested on each spirometer once and the
order of spirometers was changed between subjects ac-
cording to a Latin square design. Since each subject pro-
vided a series of measurements it could not be assumed
that a classical three-way-ANOVA, requiring independ-
ent statistical errors within subjects, would be appropri-
ate. We therefore also considered two mixed linear mod-
els, one with random individual temporal trends and the
other one assuming a first order autoregressive covariance
structure of errors within each subject. These two analy-
ses yielded very similar point estimates, standard errors
and p-values as the classical three-way-ANOVA.
Since device was a significant factor in all series, we
conducted pair wise comparisons of adjusted device-
specific means using the simulation test supplied in the
GLM-procedure of SAS. All analyses were conducted
with SAS V8.2 and STATA 8.0.
Results
Figure 1
Device-specific mean
(and 95% CI) devia-
tion in percent from
personal mean FVC
calculated across re-
sults taken at all de-
vices in test series 1.
Figure 2
Device-specific mean
(and 95% CI) devia-
tion in percent from
personal mean FVC
calculated across re-
sults taken at all de-
vices in test series 2.
Figure 3
Device-specific mean
(and 95% CI) devia-
tion in percent from
personal mean FVC
calculated across
results taken at all
devices in test 
series 3.
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Our study demonstrates that comparison of
spirometers in the field, ie with human subjects
under biologic conditions, is of paramount impor-
tance in the planning, conducting and quality as-
surance of epidemiological studies. This is partic-
ularly true for multi-centre studies and long-term
follow-up investigations. We have shown that al-
though all devices comply with the ATS standards
of accurate instruments, and all calibrations being
within the required precision, lung function test
results taken under biologic conditions did differ
significantly between instruments. Environmental
conditions such as temperature, air pressure, hu-
midity and fieldworker were the same for the
tested instruments within each test series, thus do
not explain our results.
The first two test series led to the informed de-
cision about the reuse of the SAPALDIA 1 spirom-
eters in the follow up study [8]. We first discuss the
very important finding of systematic differences
observed between two generations of the same de-
vice. 
We then interpret the random variation of
means measured across SAPALDIA devices, Sen-
sormedics 2400 and the Biomedin spirometers that
were widely used in ECRHS.
Systematic differences
To our surprise, the two Vmax devices pro-
vided systematically and substantially lower meas-
urements in all parameters. Both Sensormedics
2200 and Vmax use flow-sensing technology (heated
wire). The systematic differences may be due to
both hardware and software. Computer software
has been described as a major source of discrepan-
cies and may be one reason for our findings [13].
Details about changes in technological principles
and software algorithms are not published or ac-
cessible; thus, the causes of the differences ob-
served in these comparisons taken among biolog-
ical testing conditions are not easily revealed.
Calibrations were all within the required 99%
to 101% of the volume and only one syringe has
been used for these Sensormedics devices. Linn et
al. showed that a 1% difference in air volume read-
outs of a syringe can be a source of appreciable
error in spirometric data [14]. Yet this should not
lead to systematic differences given that each test
series involved several calibrations. Moreover no
systemtatic difference was observed between
SAPALDIA devices and the Biomedin instruments
although the latter were calibrated with another 3-
litre-syringe. Thus, it is highly unlikely that the
lower measurements in the Vmax spirometers can
be explained by calibration problems.
For the older spirometers (Sensormedics
2200, 2400), temperature and barometric pressure
are measured in the ambient air and put into the
system manually by the technician. Sensormedics
Vmax devices contained inbuilt temperature and
barometric pressure sensors with the respective
software. To our knowledge, there is no published
report available about the influence of a changed
technique of temperature and barometric pressure
assessment in flow-sensing spirometers. Never-
theless, for volume measurements, deviations of up
to 6% in FVC and FEV1 have been found due to
the altered assessment of temperature [15]. Linn et
al. describe for electronic rolling-seal spirometers
that the temperature reading in the computer soft-
ware was updated whenever temperature changed
by more than 0.2 °C [14]. In contrast, for spirom-
eters with manually entered temperature, the up-
date of temperature is done at calibration checks
and appreciable measurement variation may occur
because of imprecision in temperature measure-
ments. Given our repeated calibrations and the
rather stable temperature during all test series,
temperature is a plausible source of random varia-
tion across devices but unlikely to explain the sys-
tematic differences. Software algorithms cannot be
investigated in full detail by the user of devices;
thus, undisclosed differences in BTPS corrections
would not be detected.
Most importantly, our results demonstrate
that technological changes and improvements can
lead to systematically different readings even if all
instruments fulfil the required technical quality
criteria. New devices are usually tested in the lab-
oratory only with the ATS 24 waveforms. The
major advantage of our approach is the use of
human subjects rather than machines to compare
devices. This is a more realistic and relevant sce-
nario with several potentially important differ-
ences. First, the gas concentrations and thermal
conductivity of exhaled air differs from the ambi-
ent air; second, turbulence during exhalation is not
simulated with the machines; third, the tempera-
ture profile of exhaled air is not taken into account
in these tests. Effects of changes in the tempera-
ture of the spirometer or the humidity of the ex-
haled air are not tested in the mechanical wave-
form tests. Gilliland et al. showed significant asso-
ciations between BTPS corrected FEV1 and
spirometer temperature (–0.24% per 1 degree
Celsius) [16]. All these factors may contribute to
systematic differences of test results conducted in
humans, under field conditions. We did not con-
duct wave form comparisons, thus we do not know
to what extent laboratory tests would come to the
same conclusions.
Precision
After exclusion of the Vmax devices, our tests
showed much smaller differences between the
mean measurements. We interpret these devia-
tions as random rather than systematic device-spe-
cific effects; test series 1 and 3 that included all of
the 8 SAPALDIA Sensormedics devices give no in-
dication of systematic errors. For example, instru-
Discussion
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ment S2 ranked highest in series 2 but not in se-
ries 3. Moreover, the ranking of devices in these
series was not associated with the ranking observed
across the same devices in 1992 [11]. Therefore,
our comparisons indicate that the combined
sources of variability encountered in repeated test-
ing of lung function under biologic conditions may
lead to differences within a narrow range. 
All deviations lie within ±3% for FVC, FEV1
and even for FEF50. Other studies reported devi-
ations of up to 6.2% for FVC and 5.8% for FEV1
compared to a reference [17, 18]. American Tho-
racic Society (ATS) standards [12] allow individual
spirometers’ volume measurements to differ by
±3% from a reference instrument. The minimal
recommendations for diagnostic spirometry for
the range of 0.5 to 8 litres are ±3% of the readings
for FVC as well as for FEV1. For the FEF50 the
accuracy should lie within ±5% for a range of 7
litres [12].
The fact that these small differences between
devices reached statistical significance is a conse-
quence of the sample size. With one exception due
to a technical problem, differences in the 1992 test
were not statistically significant but of similar size.
Künzli et al. reported deviations between the eight
SAPALDIA devices of up to 3.9% for FVC and up
to 2.8% for FEV1. In our study, we found a maxi-
mal variation in average deviations from personal
means across the spirometers (Vmax device ex-
cluded) in test series 1–3 of up to 2.6% for FVC,
2.4% for FEV1 and 2.8% for FEF50 (figure 1; table
available upon request). 
It was reassuring to see that the eight Sen-
sormedics 2200 generated comparable results,
without evidence for systematic errors even
though the instruments had been used for more
than ten years. All devices compared well to the dry
seal spirometer, ie our “reference device”; thus, a
general “ageing” effect among the flow sensing
Sensormedics 2200 is unlikely unless “ageing” had
identical effects on both types of spirometers [11].
We conclude that device validity and accuracy are
not a major concern in SAPALDIA 2. 
The high agreement between Sensormedics
2200, Sensormedics 2400 and the Biomedin
spirometers is particularly important for ECRHS
II where the vast majority of centres used either
Biomedin or Sensormedics. Therefore, device-
specific deviations appear an unlikely source of
errors among those centres [9].
In studies investigating potentially “small ef-
fects” such as in air pollution research the observed
differences across the SAPALDIA devices may still
be a source of bias or noise. Long-term multi-
centre studies may thus adopt various strategies to
minimise errors. The use of a single device and
team, if feasible, strongly reduces the risk of sys-
tematic errors. Studies involving several devices
and teams may rotate the instruments to prevent
systematic errors. 
Both long-term cohort studies as well as clin-
ical laboratories need to take potential systematic
and random errors into account in the planning of
studies and the transition to newer technologies.
Quality control programs ought to conduct com-
parisons under biological conditions. Test cycles
ought to include a well maintained certified device
that has not undergone hard- or software modifi-
cations as this can serve as a point of reference in
times of technological advances. 
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